225 related articles for article (PubMed ID: 28838275)
61. Epigenetic Biomarkers in Colorectal Cancer.
Verma M; Kumar V
Mol Diagn Ther; 2017 Apr; 21(2):153-165. PubMed ID: 27878475
[TBL] [Abstract][Full Text] [Related]
62. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
63. [Circulating tumor DNA and targeted therapy in colorectal cancer].
Huang YT; Xu JM
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):161-165. PubMed ID: 29575832
[TBL] [Abstract][Full Text] [Related]
64. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
65. Methylation of a panel of genes in peripheral blood leukocytes is associated with colorectal cancer.
Luo X; Huang R; Sun H; Liu Y; Bi H; Li J; Yu H; Sun J; Lin S; Cui B; Zhao Y
Sci Rep; 2016 Jul; 6():29922. PubMed ID: 27453436
[TBL] [Abstract][Full Text] [Related]
66. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
Herbst A; Vdovin N; Gacesa S; Ofner A; Philipp A; Nagel D; Holdt LM; Op den Winkel M; Heinemann V; Stieber P; Graeven U; Reinacher-Schick A; Arnold D; Ricard I; Mansmann U; Hegewisch-Becker S; Kolligs FT
Int J Cancer; 2017 May; 140(9):2134-2144. PubMed ID: 28124380
[TBL] [Abstract][Full Text] [Related]
67. Early-onset colorectal cancer: a separate subset of colorectal cancer.
Silla IO; Rueda D; Rodríguez Y; García JL; de la Cruz Vigo F; Perea J
World J Gastroenterol; 2014 Dec; 20(46):17288-96. PubMed ID: 25516639
[TBL] [Abstract][Full Text] [Related]
68. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
[TBL] [Abstract][Full Text] [Related]
69. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer.
Kouba E; Cheng L
Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200
[No Abstract] [Full Text] [Related]
70. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas.
Zhang X; Song YF; Lu HN; Wang DP; Zhang XS; Huang SL; Sun BL; Huang ZG
World J Gastroenterol; 2015 Mar; 21(9):2629-37. PubMed ID: 25759530
[TBL] [Abstract][Full Text] [Related]
71. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
[TBL] [Abstract][Full Text] [Related]
72. Circulating tumour DNA in colorectal cancer management.
Cohen R; Platell CF; McCoy MJ; Meehan K; Fuller K
Br J Surg; 2023 Jun; 110(7):773-783. PubMed ID: 37190784
[TBL] [Abstract][Full Text] [Related]
73. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
74. Quantification of Plasma Cell-Free Circulating DNA at Different Stages of Colorectal Cancer.
Agah S; Akbari A; Talebi A; Masoudi M; Sarveazad A; Mirzaei A; Nazmi F
Cancer Invest; 2017 Nov; 35(10):625-632. PubMed ID: 29243990
[TBL] [Abstract][Full Text] [Related]
75. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer.
Li J; Chen Y; Guo X; Zhou L; Jia Z; Tang Y; Lin L; Liu W; Ren C
Tumour Biol; 2016 Jul; 37(7):8765-73. PubMed ID: 26743779
[TBL] [Abstract][Full Text] [Related]
77. The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.
Chen WY; Zhao XJ; Yu ZF; Hu FL; Liu YP; Cui BB; Dong XS; Zhao YS
Int J Clin Exp Pathol; 2015; 8(6):7092-101. PubMed ID: 26261602
[TBL] [Abstract][Full Text] [Related]
78. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
Lecomte T; Berger A; Zinzindohoué F; Micard S; Landi B; Blons H; Beaune P; Cugnenc PH; Laurent-Puig P
Int J Cancer; 2002 Aug; 100(5):542-8. PubMed ID: 12124803
[TBL] [Abstract][Full Text] [Related]
79. Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.
Igder S; Zamani M; Fakher S; Siri M; Ashktorab H; Azarpira N; Mokarram P
Dis Markers; 2024; 2024():9943412. PubMed ID: 38380073
[TBL] [Abstract][Full Text] [Related]
80. Non-coding landscapes of colorectal cancer.
Ragusa M; Barbagallo C; Statello L; Condorelli AG; Battaglia R; Tamburello L; Barbagallo D; Di Pietro C; Purrello M
World J Gastroenterol; 2015 Nov; 21(41):11709-39. PubMed ID: 26556998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
